Considering the multiple functions of FSTL-1, such as a cardiokine, myokine, and inflammatory modulator, circulating FSTL-1 may be a promising biomarker for determining the status of CV, inflammation, and physical performance and predicting adverse clinical outcomes in HD patients. This evidence concerns the gene FSTL1 and Huntington disease.